Published 6 days ago • loading... • Updated 5 days ago

FDA approves more broadly protective meningococcal vaccine

Summary by Medical Xpress

The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease (IMD), according to a press release from GlaxoSmithKline (GSK).

11 Articles

All

Left

Center

Right

HealthDay

+2 Reposted by 2 other sources

FDA Approves More Broadly Protective Meningococcal Vaccine

TUESDAY, Feb. 18, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive

5 days ago

Read Full Article

healtheconomics.com

FDA Approves GSK's PENMENVY: A Comprehensive 5-in-1 Meningococcal Vaccine for Adolescents and Young Adults

The U.S. FDA has approved GSK’s PENMENVY, a novel 5-in-1 vaccine designed to protect against the five major serogroups of Neisseria meningitidis: A, B, C, W, and Y. Targeted at individuals aged 10 through 25 years, this vaccine aims to simplify the meningococcal vaccination process by combining elements from GSK’s existing BEXSERO and MENVEO vaccines. This integration reduces the number of injections needed, potentially improving vaccination rat…

5 days ago

Read Full Article

Medical Xpress

FDA approves more broadly protective meningococcal vaccine

5 days ago

Read Full Article

contemporarypediatrics.com

Reacting to the meningococcal ABCWY vaccine approval with Donna Hallas, PhD, PPCNP-BC

Nurse practitioner Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN offers her thoughts on the recent FDA approval of GSK's meningococcal ABCWY vaccine.

6 days ago

Read Full Article